<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078125</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU KMAly</org_study_id>
    <nct_id>NCT05078125</nct_id>
  </id_info>
  <brief_title>Electrocardiographic and Cardiac Magnetic Resonance Predictors of Ventricular Arrhythmias in Cardiomyopathic Patients</brief_title>
  <official_title>ECG and CMR for Predicting PVCs in Cardiomyopathic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess ECG changes for predicting ventricular arrhythmia in&#xD;
      cardiomyopathic patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess ECG markers based on 24-hour Holter ECG recordings for predicting&#xD;
      ventricular arrhythmia in patients with Structural Heart disease who have left ventricular&#xD;
      dysfunction and Left Ventricular Ejection Fraction ≤40%. With special concerns to underlying&#xD;
      structural abnormalities in cardiomyopathic patients using Cardiac Magnetic Resonance to&#xD;
      determine ventricular function, scar distribution, and grey zone analysis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Twenty-four hours Holter monitoring after Magnetic Resonance Imaging</measure>
    <time_frame>One year</time_frame>
    <description>24 Holter monitoring to detect PVCs burden which is defined as ≥10% of total beats</description>
  </primary_outcome>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Premature Ventricular Complex</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter monitoring</intervention_name>
    <description>24 hours Holter monitoring</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is anticipated to include all consecutive eligible cardiomyopathic patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ischemic and non-ischemic cardiomyopathy, EF &lt; 40 %&#xD;
&#xD;
          -  Patient haemodynamically stable&#xD;
&#xD;
          -  Patients accept to make test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with underlying arrhythmia ex heart block or atrial arrhythmia like PACs, AF.&#xD;
&#xD;
          2. Patients on arrhythmogenic drugs ex digitalis, amiodarone.&#xD;
&#xD;
          3. Patients on underlying Pacemaker device or CRT-D.&#xD;
&#xD;
          4. Patients with MI in less than 40 days&#xD;
&#xD;
          5. Patients refuse to make test .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <results_reference>
    <citation>Mathew T, Williams L, Navaratnam G, Rana B, Wheeler R, Collins K, Harkness A, Jones R, Knight D, O'Gallagher K, Oxborough D, Ring L, Sandoval J, Stout M, Sharma V, Steeds RP; British Society of Echocardiography Education Committee. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract. 2017 Jun;4(2):G1-G13. doi: 10.1530/ERP-16-0037.</citation>
    <PMID>28592613</PMID>
  </results_reference>
  <results_reference>
    <citation>Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, Duboc D, Gimeno J, de Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016 Jun 14;37(23):1850-8. doi: 10.1093/eurheartj/ehv727. Epub 2016 Jan 19. Review.</citation>
    <PMID>26792875</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma E, Arunachalam K, Di M, Chu A, Maan A. PVCs, PVC-Induced Cardiomyopathy, and the Role of Catheter Ablation. Crit Pathw Cardiol. 2017 Jun;16(2):76-80. doi: 10.1097/HPC.0000000000000106. Review.</citation>
    <PMID>28509708</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee DC, Markl M, Dall'Armellina E, Han Y, Kozerke S, Kuehne T, Nielles-Vallespin S, Messroghli D, Patel A, Schaeffter T, Simonetti O, Valente AM, Weinsaft JW, Wright G, Zimmerman S, Schulz-Menger J. The growth and evolution of cardiovascular magnetic resonance: a 20-year history of the Society for Cardiovascular Magnetic Resonance (SCMR) annual scientific sessions. J Cardiovasc Magn Reson. 2018 Jan 31;20(1):8. doi: 10.1186/s12968-018-0429-z. Review.</citation>
    <PMID>29386064</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 17, 2021</last_update_submitted>
  <last_update_submitted_qc>October 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Khaled Mohamed Aly</investigator_full_name>
    <investigator_title>Resident doctor of cardiology .Luxor International Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

